Home › Companies › SELLAS Life Sciences Group, Inc. › 2025-2026

SELLAS Life Sciences Group, Inc. 2025-2026 Proxy Voting Records

Compiled from SEC Form N-PX filings and SELLAS Life Sciences Group, Inc.’s Form 8-K, filed 2026-06-18 (Item 5.07 on EDGAR). Page generated 04 October 2026.

6Reported items
135Asset managers
748Fund votes
2026-06-16Meeting date

Proxy season: 2025-2026

Explore SELLAS Life Sciences Group, Inc. in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by SELLAS Life Sciences Group, Inc.

These tallies are SELLAS Life Sciences Group, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2026-06-18 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

SELLAS Life Sciences Group, Inc. — official shareholder meeting results, meeting held 2026-06-16
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Outcome
Elect Director: Robert Van Nostrand	66,490,143	--	--	4,544,035	44,477,593	Majority: yes
Elect Director: Jane Wasman	65,928,448	--	--	5,105,730	44,477,593	Majority: yes
Proposal 4 The Company's stockholders approved the non-binding, advisory resolution on the executive compensation of the Company's named executive officers.	52,930,792	15,906,732	2,196,654	--	44,477,593	Majority: yes
Proposal 5 The Company's stockholders approved an adjournment of the Annual Meeting, if necessary, to solicit additional proxies in favor of proposals 1, 2, 3 and 4.	90,571,992	22,200,030	2,739,749	--	--	Majority: yes

Source: SELLAS Life Sciences Group, Inc., Form 8-K, filed with the SEC on 2026-06-18 — read the filing on EDGAR.

How asset managers voted at the SELLAS Life Sciences Group, Inc. 2025-2026 meeting

Each item below shows how the 135 asset managers that disclosed a SELLAS Life Sciences Group, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of SELLAS Life Sciences Group, Inc.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. THE ADVISORY APPROVAL OF THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS.

SECTION 14A SAY-ON-PAY VOTESMajority of the votes cast: yes

Combines 4 wordings of this item as funds reported it.

77% Majority: yes · of votes cast

FOR 77%AGAINST 23%

FOR: 52,930,792AGAINST: 15,906,732

SELLAS Life Sciences Group, Inc.’s own tally for this item (“Proposal 4 The Company's stockholders approved the non-binding, advisory resolution on the executive compensation of the Company's named executive officers.”): 52,930,792 for, 15,906,732 against, per its Form 8-K filed 2026-06-18 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 186,032,574 outstanding shares: 28% for, 9% against (37% of the company cast a for/against vote).

The 135 asset managers below cast 60% of the shares they voted on this item FOR (5,596,393 for, 3,696,526 against).

FOR 60%AGAINST 40%

FOR: 5,596,393 (60.2%)AGAINST: 3,696,526 (39.8%)ABSTAIN: 1 (0.0%)

Largest asset managers voting on “THE ADVISORY APPROVAL OF THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS.” at SELLAS Life Sciences Group, Inc., 2025-2026
Asset manager	For	Against	Abstain	Vote
Edward D. Jones & Co., L.P.	0	1,673,842	0	Against
State Street	1,369,900	9,118	0	For
BlackRock	944,301	22,531	0	For
Northern Trust	633,663	7,853	0	For
Vanguard	529,692	1,668	1	For
MELLON INVESTMENTS Corp	0	344,490	0	Against
Invesco	0	278,394	0	Against
Fidelity	251,351	0	0	For
Wellington	246,697	0	0	For
GEODE CAPITAL MANAGEMENT, LLC	239,817	0	0	For
Lincoln Financial	114,100	104,657	0	For
MARSHALL WACE, LLP	168,635	0	0	For
AllianceBernstein	0	163,940	0	Against
Two Sigma	0	138,893	0	Against
Equitable	27,408	107,230	0	Against
Goldman Sachs	131,585	0	0	For
FRANKLIN ADVISERS INC	0	104,657	0	Against
WELLS FARGO ADVISORS FINANCIAL NETWORK, LLC	100,500	0	0	For
Tema ETF Trust	91,762	0	0	For
AQR	0	89,797	0	Against
PARAMETRIC PORTFOLIO ASSOCIATES LLC	0	81,454	0	Against
Direxion Shares ETF Trust	0	77,523	0	Against
Rafferty Asset Management, LLC	0	77,523	0	Against
Global X	73,946	0	0	For
SEI	62,838	0	0	For

Showing the 25 largest of 135 asset managers. See all 135 in the interactive database.

2. To approve an amendment to the Company's 2023 Amended and Restated Equity Incentive plan (the "2023 Equity Plan") to increase the number of shares of Common Stock authorized for issuance under the 2023 Equity Plan by 20,000,000 shares.

COMPENSATION

Combines 2 wordings of this item as funds reported it.

99.6% fund support · no official result

FOR 99.6%

The 38 asset managers below cast 99.6% of the shares they voted on this item FOR (2,313,925 for, 7,520 against).

FOR: 2,313,925 (99.7%)AGAINST: 7,520 (0.3%)

Largest asset managers voting on “To approve an amendment to the Company's 2023 Amended and Restated Equity Incentive plan (the "2023 Equity Pla” at SELLAS Life Sciences Group, Inc., 2025-2026
Asset manager	For	Against	Vote
Vanguard	449,229	1,242	For
BlackRock	337,461	0	For
State Street	294,657	384	For
Fidelity	230,805	0	For
Lincoln Financial	218,757	0	For
Equitable	134,638	0	For
Invesco	112,441	0	For
Tema ETF Trust	91,762	0	For
Direxion Shares ETF Trust	77,523	0	For
Global X	73,946	0	For
AQR	40,390	0	For
ProShares	34,720	0	For
Bridge Builder Trust	32,612	0	For
SEI	31,400	0	For
Charles Schwab	24,023	0	For
John Hancock	20,917	0	For
Goldman Sachs	20,717	0	For
Calvert	14,065	0	For
AIG/SunAmerica	13,988	0	For
Venerable Variable Insurance Trust	12,946	0	For
Voya	11,969	0	For
Principal	10,828	0	For
Nationwide	8,577	0	For
TIAA	6,446	0	For
Amplify ETF Trust	0	3,894	Against

Showing the 25 largest of 38 asset managers. See all 38 in the interactive database.

3. The election of two (2) Class I directors to serve on our Board for a three-year term expiring on the date of the 2029 annual meeting of stockholders: Jane Wasman

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

93% Majority: yes · of votes cast

FOR 93%7%

FOR: 65,928,448WITHHELD: 5,105,730

SELLAS Life Sciences Group, Inc.’s own tally for this item (“Elect Director: Jane Wasman”): 65,928,448 for, 5,105,730 withheld, per its Form 8-K filed 2026-06-18 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 186,032,574 outstanding shares: 35% for, 3% withheld (38% of the company cast a for/withheld vote).

The 37 asset managers below cast 100% of the shares they voted on this item FOR (2,192,050 for, 0 against).

FOR 95%

FOR: 2,192,050 (94.5%)ABSTAIN: 127,396 (5.5%)

Largest asset managers voting on “The election of two (2) Class I directors to serve on our Board for a three-year term expiring on the date of ” at SELLAS Life Sciences Group, Inc., 2025-2026
Asset manager	For	Abstain	Vote
Vanguard	448,637	1,834	For
BlackRock	337,461	0	For
State Street	294,669	372	For
Fidelity	230,805	0	For
Lincoln Financial	218,757	0	For
Equitable	27,408	107,230	Abstain
Invesco	112,441	0	For
Tema ETF Trust	91,762	0	For
Direxion Shares ETF Trust	77,523	0	For
Global X	73,946	0	For
AQR	40,390	0	For
ProShares	34,720	0	For
Bridge Builder Trust	32,612	0	For
SEI	31,400	0	For
Charles Schwab	24,023	0	For
John Hancock	20,917	0	For
Goldman Sachs	20,717	0	For
Calvert	0	14,065	Abstain
AIG/SunAmerica	13,988	0	For
Venerable Variable Insurance Trust	12,946	0	For
Voya	11,969	0	For
Principal	10,828	0	For
Nationwide	8,577	0	For
TIAA	6,446	0	For
Amplify ETF Trust	0	3,894	Abstain

Showing the 25 largest of 37 asset managers. See all 37 in the interactive database.

4. The election of two (2) Class I directors to serve on our Board for a three-year term expiring on the date of the 2029 annual meeting of stockholders: Robert Van Nostrand

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

94% Majority: yes · of votes cast

FOR 94%

FOR: 66,490,143WITHHELD: 4,544,035

SELLAS Life Sciences Group, Inc.’s own tally for this item (“Elect Director: Robert Van Nostrand”): 66,490,143 for, 4,544,035 withheld, per its Form 8-K filed 2026-06-18 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 186,032,574 outstanding shares: 36% for, 2% withheld (38% of the company cast a for/withheld vote).

The 37 asset managers below cast 100% of the shares they voted on this item FOR (2,299,280 for, 0 against).

FOR 99.1%

FOR: 2,299,280 (99.1%)ABSTAIN: 20,166 (0.9%)

Largest asset managers voting on “The election of two (2) Class I directors to serve on our Board for a three-year term expiring on the date of ” at SELLAS Life Sciences Group, Inc., 2025-2026
Asset manager	For	Abstain	Vote
Vanguard	448,637	1,834	For
BlackRock	337,461	0	For
State Street	294,669	372	For
Fidelity	230,805	0	For
Lincoln Financial	218,757	0	For
Equitable	134,638	0	For
Invesco	112,441	0	For
Tema ETF Trust	91,762	0	For
Direxion Shares ETF Trust	77,523	0	For
Global X	73,946	0	For
AQR	40,390	0	For
ProShares	34,720	0	For
Bridge Builder Trust	32,612	0	For
SEI	31,400	0	For
Charles Schwab	24,023	0	For
John Hancock	20,917	0	For
Goldman Sachs	20,717	0	For
Calvert	0	14,065	Abstain
AIG/SunAmerica	13,988	0	For
Venerable Variable Insurance Trust	12,946	0	For
Voya	11,969	0	For
Principal	10,828	0	For
Nationwide	8,577	0	For
TIAA	6,446	0	For
Amplify ETF Trust	0	3,894	Abstain

Showing the 25 largest of 37 asset managers. See all 37 in the interactive database.

5. The approval of any postponement or adjournment of the 2026 Annual Meeting, from time to time, if necessary, to solicit additional proxies if there are not sufficient votes at the time of the 2026 Annual Meeting to adopt the proposals set forth above or to establish a quorum.

CORPORATE GOVERNANCEMajority of the votes cast: yes

80% Majority: yes · of votes cast

FOR 80%AGAINST 20%

FOR: 90,571,992AGAINST: 22,200,030

SELLAS Life Sciences Group, Inc.’s own tally for this item (“Proposal 5 The Company's stockholders approved an adjournment of the Annual Meeting, if necessary, to solicit additional proxies in favor of proposals 1, 2, 3 and 4.”): 90,571,992 for, 22,200,030 against, per its Form 8-K filed 2026-06-18 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 186,032,574 outstanding shares: 48.7% for, 12% against (61% of the company cast a for/against vote).

The 37 asset managers below cast 63% of the shares they voted on this item FOR (1,471,110 for, 848,334 against).

FOR 63%AGAINST 37%

FOR: 1,471,110 (63.4%)AGAINST: 848,334 (36.6%)ABSTAIN: 1 (0.0%)

Largest asset managers voting on “The approval of any postponement or adjournment of the 2026 Annual Meeting, from time to time, if necessary, t” at SELLAS Life Sciences Group, Inc., 2025-2026
Asset manager	For	Against	Abstain	Vote
Vanguard	450,465	5	1	For
BlackRock	337,461	0	0	For
State Street	580	294,461	0	Against
Fidelity	230,805	0	0	For
Lincoln Financial	0	218,757	0	Against
Equitable	27,408	107,230	0	Against
Invesco	112,441	0	0	For
Tema ETF Trust	91,762	0	0	For
Direxion Shares ETF Trust	0	77,523	0	Against
Global X	73,946	0	0	For
AQR	0	40,390	0	Against
ProShares	0	34,720	0	Against
Bridge Builder Trust	32,612	0	0	For
SEI	31,400	0	0	For
Charles Schwab	24,023	0	0	For
John Hancock	0	20,917	0	Against
Goldman Sachs	20,717	0	0	For
Calvert	0	14,065	0	Against
AIG/SunAmerica	0	13,988	0	Against
Venerable Variable Insurance Trust	12,946	0	0	For
Voya	11,969	0	0	For
Principal	0	10,828	0	Against
Nationwide	8,577	0	0	For
TIAA	0	6,446	0	Against
Amplify ETF Trust	3,894	0	0	For

Showing the 25 largest of 37 asset managers. See all 37 in the interactive database.

6. The ratification of the appointment by our Audit Committee of Baker Tilly US, LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026.

AUDIT-RELATED

99.9% fund support · no official result

FOR 99.9%

The 37 asset managers below cast 99.9% of the shares they voted on this item FOR (2,319,433 for, 12 against).

FOR: 2,319,433 (100.0%)AGAINST: 12 (0.0%)

Largest asset managers voting on “The ratification of the appointment by our Audit Committee of Baker Tilly US, LLP as our independent registere” at SELLAS Life Sciences Group, Inc., 2025-2026
Asset manager	For	Against	Vote
Vanguard	450,470	0	For
BlackRock	337,461	0	For
State Street	295,029	12	For
Fidelity	230,805	0	For
Lincoln Financial	218,757	0	For
Equitable	134,638	0	For
Invesco	112,441	0	For
Tema ETF Trust	91,762	0	For
Direxion Shares ETF Trust	77,523	0	For
Global X	73,946	0	For
AQR	40,390	0	For
ProShares	34,720	0	For
Bridge Builder Trust	32,612	0	For
SEI	31,400	0	For
Charles Schwab	24,023	0	For
John Hancock	20,917	0	For
Goldman Sachs	20,717	0	For
Calvert	14,065	0	For
AIG/SunAmerica	13,988	0	For
Venerable Variable Insurance Trust	12,946	0	For
Voya	11,969	0	For
Principal	10,828	0	For
Nationwide	8,577	0	For
TIAA	6,446	0	For
Amplify ETF Trust	3,894	0	For

Showing the 25 largest of 37 asset managers. See all 37 in the interactive database.

Largest SELLAS Life Sciences Group, Inc. shareholders voting in 2025-2026

Ranked by the number of SELLAS Life Sciences Group, Inc. shares each manager voted on the most widely held ballot item of the 2025-2026 meeting, shown as a share of the 186,032,574 shares outstanding at the time of that meeting.

Top SELLAS Life Sciences Group, Inc. shareholders by shares voted, 2025-2026
#	Asset manager	% of shares outstanding
1	Edward D. Jones & Co., L.P.	0.90%
2	State Street	0.74%
3	BlackRock	0.52%
4	Northern Trust	0.34%
5	Vanguard	0.29%
6	MELLON INVESTMENTS Corp	0.19%
7	Invesco	0.15%
8	Fidelity	0.14%
9	Wellington	0.13%
10	GEODE CAPITAL MANAGEMENT, LLC	0.13%

Reported SELLAS Life Sciences Group, Inc. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

SELLAS Life Sciences Group, Inc. beneficial owners on record for the 2025-2026 proxy season
Holder	% outstanding	Disclosure
BlackRock	6.56%	13F
Vanguard Group	4.55%	13F
State Street	4.51%	13F
Anson Funds Management LP	4.02%	13G
Citadel Advisors	2.62%	13F
Northern Trust	0.69%	13F
Angelos M. Stergiou, President, Chief Executive Officer and Director	0.61%	DEF14A
Millennium Management	0.54%	13F
Morgan Stanley	0.48%	13F
Invesco	0.38%	13F

Percentages above are of 186,032,574 shares outstanding, as reported by SELLAS Life Sciences Group, Inc. on its Form 10-Q dated 2026-05-11 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from SELLAS Life Sciences Group, Inc.’s 10-Q dated 2026-05-11. This page is a static snapshot rebuilt weekly on 04 October 2026; a live search always shows the current data.

At SELLAS Life Sciences Group, Inc.'s shareholder meeting held 2026-06-16, in the 2025-2026 proxy season, 135 asset managers reported how they voted in their SEC Form N-PX filings, covering 748 separate fund positions. Their filings are grouped here into 6 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — THE ADVISORY APPROVAL OF THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS. — FOR was 77% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: SELLAS Life Sciences Group, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2026-06-18.

SELLAS Life Sciences Group, Inc. proxy season coverage: 2025-2026 (this page).